Antibodies that bind il-23

Abstract

The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.

1 . An antibody that binds to the p19 subunit of human IL-23 comprising a light chain and a heavy chain, wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions LCDR1, LCDR2, and LCDR3, and the HCVR comprises complementarity determining regions HCDR1, HCDR2, and HCDR3, wherein LCDR1 consists of amino acid sequence SEQ ID NO:4, LCDR2 consists of amino acid sequence SEQ ID NO:5, LCDR3 consists of amino acid sequence SEQ ID NO:6, HCDR1 consists of amino acid sequence SEQ ID NO:1, HCDR2 consists of amino acid sequence SEQ ID NO:2, and HCDR3 consists of amino acid sequence SEQ ID NO:3. 
     
     
         2 . An antibody that binds to the p19 subunit of human IL-23 comprising a light chain and a heavy chain, wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the LCVR comprises amino acid sequence SEQ ID NO: 8 and the HCVR comprises amino acid sequence SEQ ID NO: 7. 
     
     
         3 . An antibody that binds to the p19 subunit of human IL-23 comprising a light chain and a heavy chain, wherein the light chain comprises amino acid sequence SEQ ID NO: 10 and the heavy chain comprises amino acid sequence SEQ ID NO: 9. 
     
     
         4 . An antibody that binds to the p19 subunit of human IL-23 comprising two light chains and two heavy chains, wherein each light chain comprises amino acid sequence SEQ ID NO: 10 and each heavy chain comprises SEQ ID NO: 9. 
     
     
         5 . A DNA molecule comprising a polynucleotide sequence encoding a light chain polypeptide having the amino acid sequence SEQ ID NO: 10. 
     
     
         6 . A DNA molecule comprising a polynucleotide sequence encoding a heavy chain polypeptide having the amino acid sequence SEQ ID NO: 9. 
     
     
         7 . A recombinant host cell comprising the DNA molecule of  claim 5  and the DNA molecule of  claim 6 , which cell is capable of expressing an antibody comprising a heavy chain and a light chain, wherein the amino acid sequence of the heavy chain is SEQ ID NO: 9 and the amino acid sequence of the light chain is SEQ ID NO: 10. 
     
     
         8 . A process for producing an antibody that binds to the p19 subunit of human IL-23 comprising a heavy chain and a light chain, wherein the heavy chain comprises amino acid sequence SEQ ID NO: 9 and the light chain comprises the amino acid sequence of SEQ ID NO: 10, said process comprising the steps of:
 a) cultivating a recombinant host cell of  claim 7 , under conditions such that said antibody is expressed; and   b) recovering from said host cell the expressed antibody.   
     
     
         9 . An antibody produced by the process of  claim 8 . 
     
     
         10 . A pharmaceutical composition comprising an antibody of  claim 4  and one or more pharmaceutically acceptable carriers, diluents or excipients. 
     
     
         11 . A pharmaceutical composition comprising an antibody of  claim 9  and one or more pharmaceutically acceptable carriers, diluents or excipients. 
     
     
         12 . A method of treating or preventing an autoimmune or inflammatory condition in a patient, comprising administering to a patient in need thereof an effective amount of an antibody of  claim 4 , wherein the condition is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. 
     
     
         13 . A method of treating or preventing an autoimmune or inflammatory condition in a patient, comprising administering to a patient in need thereof an effective amount of an antibody of  claim 9 , wherein the condition is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. 
     
     
         14 . A method of treating or preventing cancer in a patient, comprising administering to a patient in need thereof an effective amount of an antibody of  claim 4 , wherein the cancer is melanoma, colon, ovarian, head and neck, lung, breast, or stomach cancer. 
     
     
         15 . A method of treating or preventing cancer in a patient, comprising administering to a patient in need thereof an effective amount of an antibody of  claim 9 , wherein the cancer is melanoma, colon, ovarian, head and neck, lung, breast, or stomach cancer.